---
title: "Understanding the Market | CUTIA-B rises over 3% CU-20101 (Injectable Type A Botulinum Toxin) completes Phase III clinical trial in China"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282490883.md"
description: "CUTIA-B rose over 3%, as of the time of publication, up 3.25%, reported at HKD 4.76, with a trading volume of HKD 409,900. In terms of news, CUTIA announced today that the group has completed the Phase III clinical trial in China for CU-20101 (injectable type A botulinum toxin) for the improvement of moderate to severe glabellar lines. This clinical trial aims to evaluate the efficacy and safety of single and repeated injections of CU-20101 in treating moderate to severe glabellar lines. The clinical trial used the reference formulation Botox® (injectable type A botulinum toxin) as a control. The clinical trial is expected to complete all subject withdrawals by November 2025 and achieve database lock with positive topline results by January 2026"
datetime: "2026-04-13T05:41:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282490883.md)
  - [en](https://longbridge.com/en/news/282490883.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282490883.md)
---

# Understanding the Market | CUTIA-B rises over 3% CU-20101 (Injectable Type A Botulinum Toxin) completes Phase III clinical trial in China

According to Zhitong Finance APP, CUTIA-B (02487) rose over 3%, as of the time of writing, up 3.25% to HKD 4.76, with a trading volume of HKD 409,900.

In terms of news, CUTIA announced today that the group has completed the Phase III clinical trial in China for CU-20101 (injectable type A botulinum toxin) for the improvement of moderate to severe glabellar lines. This clinical trial aims to evaluate the efficacy and safety of single and repeated injections of CU-20101 in treating moderate to severe glabellar lines. The clinical trial used the reference formulation Botox® (injectable type A botulinum toxin) as a control. The clinical trial is expected to complete all subject withdrawals by November 2025 and achieve database lock with positive topline results by January 2026

### Related Stocks

- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [159892.CN](https://longbridge.com/en/quote/159892.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [02487.HK](https://longbridge.com/en/quote/02487.HK.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [513700.CN](https://longbridge.com/en/quote/513700.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)

## Related News & Research

- [China’s Clinical Trial Registrations Surpass 5,000 for First Time in 2025](https://longbridge.com/en/news/290539713.md)
- [Cutia Therapeutics AGM resolutions passed in shareholder vote](https://longbridge.com/en/news/290935117.md)
- [China closing in but US still leads in biotech innovation, survey finds](https://longbridge.com/en/news/290431706.md)
- [Cutia Wins NMPA Nod for Topical Anesthesia Cream, Expanding China Dermatology Portfolio](https://longbridge.com/en/news/285457203.md)